Iris Bincovich

InnoCan Pharma Corp. (OTCQB:INNPF) (CSE:INNO) (FSE: IP4) an Israel-based cannabinoids-focused pharmaceutical company, announced its interim consolidated financial results Monday for the three months ended March 31, 2024. The company reported revenues of $6.8 million, marking a 334% increase...

Innocan Pharma Corporation (CSE:INNO) (FSE: IP4) (OTCQB:INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration (FDA), for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. With the move, the...

Innocan Pharma Corporation (OTCQB:INNPF) (CSE:INNO) (FSE: IP4), a cannabinoids-focused pharmaceutical company based in Israel, announced Monday its financial results for the the year ended December 31, 2023. The company reported a nearly sixfold increase in its revenues, reaching US$13.7 million,...

Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms, reported its financial results for Q2 2023. The company's CEO, Iris Bincovich, expressed excitement about the positive trajectory and strategic...

Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) released its financial results for the three and nine months ended September 30, 2022, revealing Q3 revenue of $1.42 million, a 700% increase compared to $180,000 in the Q3 2021. Q3 2022 Financial Highlights Gross Profit - was $511,...

Cannabis-focused extraction company Ayurcann Holdings Corp. (CSE: AYUR) has partnered with Israeli pharmaceutical tech company Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) to produce its CBD topical products. Under the deal, the Toronto-based company agreed to manufacture Innocan's...